Dermal fibrosis improving effect of epoxidized unsaturated fatty acid

Epoxidized unsaturated fatty acids provide a new mechanism to address the ineffectiveness of existing treatments for skin fibrotic diseases by suppressing type I collagen expression, offering a promising antifibrotic therapy with reduced systemic side effects and local administration options.

WO2024237316A1PCT designated stage expired Publication Date: 2024-11-21THE UNIV OF TOKYO
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018177
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-16
Filing Date
2024-05-16
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current treatments for skin fibrotic diseases, such as systemic scleroderma and keloids, are often ineffective due to their irreversible nature and resistance to immune system-targeting therapies, necessitating new antifibrotic mechanisms.

Method used

Epoxidized unsaturated fatty acids, particularly epoxidized omega-3 and omega-6 fatty acids, are used to inhibit skin fibrosis by suppressing type I collagen expression and targeting lipid metabolism in the skin, offering a distinct mechanism of action compared to conventional treatments.

Benefits of technology

Epoxidized unsaturated fatty acids demonstrate potential as novel antifibrotic agents, effectively reducing skin fibrosis in both human clinical specimens and animal models, with fewer systemic side effects and the possibility of local administration, making them suitable for various skin fibrotic diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024018177_21112024_PF_FP_ABST
    Figure JP2024018177_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention addresses the problem of providing a means for improving dermal fibrosis in dermal fibrotic diseases. The present invention provides a dermal fibrosis inhibitor containing at least one selected from epoxidized unsaturated fatty acids and derivatives thereof.
Need to check novelty before this filing date? Find Prior Art

Description

The effect of epoxidized unsaturated fatty acids on improving skin fibrosis

[0001] The present invention relates to a skin fibrosis inhibitor and the like.

[0002] Chronic inflammation caused by tissue injury or autoimmune mechanisms often leads to tissue fibrosis and subsequent dysfunction. Skin diseases associated with fibrosis include systemic sclerosis (designated an intractable disease), localized scleroderma, keloids, hypertrophic scars, lupus profundus, dermatofibroma, lichen sclerosus et atrophicus, sclerosing panniculitis, nodular fasciitis, and neurofibromatosis. While the pathogenesis of these fibrotic skin diseases is gradually becoming clearer, much remains unknown. Furthermore, these skin fibrotic diseases often exhibit a strong irreversible component to the fibrosis itself, leading to resistance to existing immune-targeted treatments such as corticosteroids, resulting in insufficient therapeutic efficacy. Therefore, elucidating new mechanisms of fibrosis and developing new anti-fibrotic drugs that directly target fibrosis are desired.

[0003] On the other hand, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), known as omega-3 fatty acids, are unsaturated fatty acids found in large amounts in fish oil and other foods, and are well known as health-promoting components. These omega-3 fatty acids are oxidized to epoxidized omega-3 fatty acids (17,18-EpETE and 19,20-EpDPE) (Figure 1(A)). Furthermore, the present inventors have previously demonstrated that phospholipids containing these epoxidized omega-3 fatty acids are released from the cell membrane by PAFAH2 (platelet-activating factor acetylhydrolase 2), a type of phospholipase A2, in mast cells (Figure 1(B)) (Non-Patent Document 1). These epoxidized omega-3 fatty acids have also been shown to be involved in the control of pulmonary hypertension (Non-Patent Document 2). However, the relationship between epoxidized omega-3 fatty acids or PAFAH2 and skin fibrotic disorders has not yet been elucidated.

[0004] Shimanaka Y, et al. Nat Med. 23(11), 1287-1297 (2017)Moriyama H, et al. Nat Commun. 13(1), 3013 (2022)

[0005] In view of the above circumstances, an objective of the present invention is to provide a means for improving skin fibrosis (skin hardening) caused by skin fibrotic diseases.

[0006] The present inventors have conducted extensive research to solve the above-mentioned problems, and as a result have found that epoxidized omega-3 fatty acids have anti-fibrotic effects in the skin.The mechanism of this effect was inferred from the results of studies based on human skin clinical specimens, and further studies using cell lines, etc., and studies using experimental animals (mice) have demonstrated that epoxidized unsaturated fatty acids such as epoxidized omega-3 fatty acids and their derivatives have the potential to be new skin anti-fibrotic therapeutic agents.Based on these findings, the present invention has been completed.That is, the gist of the present invention relates to the following.

[0007] [1] A skin fibrosis inhibitor comprising one or more selected from epoxidized unsaturated fatty acids and derivatives thereof. [2] The agent according to [1], wherein the derivative of epoxidized unsaturated fatty acid is a hydroxylated epoxidized unsaturated fatty acid. [3] The agent according to [1] or [2], wherein the epoxidized unsaturated fatty acid is an epoxidized omega-3 fatty acid, an epoxidized omega-6 fatty acid, or an epoxidized omega-9 fatty acid. [4] The agent according to any of [1] to [3], wherein the epoxidized unsaturated fatty acid has 16 to 36 carbon atoms. [5] The agent according to any of [1] to [4], wherein the epoxidized unsaturated fatty acid is an epoxidized omega-3 fatty acid. [6] The agent according to any of [1] to [5], wherein the epoxidized unsaturated fatty acid is 17,18-epoxyeicosatetraenoic acid (17,18-EpETE) or 19,20-epoxydocosapentaenoic acid (19,20-EpDPE). [7] The agent according to any of [1] to [6], wherein the expression of type I collagen is suppressed. [8] A composition for preventing, ameliorating, and / or treating a skin fibrotic disease, comprising the agent according to any one of [1] to [7]. [9] The composition according to [8], wherein the skin fibrotic disease is selected from systemic sclerosis, localized scleroderma, keloid, hypertrophic scar, lupus profundus, dermatofibroma, lichen sclerosus et atrophicus, sclerosing panniculitis, nodular fasciitis, neurofibromatosis, etc.

[0008] The present invention can also be embodied in the following aspects.

[10] A method for inhibiting skin fibrosis, comprising administering to a subject one or more types selected from epoxidized unsaturated fatty acids and derivatives thereof.

[11] Use of one or more types selected from epoxidized unsaturated fatty acids and derivatives thereof for inhibiting skin fibrosis.

[12] One or more types selected from epoxidized unsaturated fatty acids and derivatives thereof for use in inhibiting skin fibrosis.

[13] Use of one or more types selected from epoxidized unsaturated fatty acids and derivatives thereof in the manufacture of a skin fibrosis inhibitor.

[14] A method for manufacturing a skin fibrosis inhibitor, comprising formulating one or more types selected from epoxidized unsaturated fatty acids and derivatives thereof.

[15] A method for preventing, ameliorating, and / or treating a skin fibrotic disease, comprising administering to a subject the agent according to any of [1] to [7].

[16] Use of the agent according to any of [1] to [7] for preventing, ameliorating, and / or treating a skin fibrotic disease.

[17] The agent according to any of [1] to [7] for use in the prevention, amelioration, and / or treatment of a skin fibrotic disease.

[18] Use of the agent according to any one of [1] to [7] in the manufacture of a composition for preventing, ameliorating, and / or treating a skin fibrotic disease.

[19] A method for manufacturing a composition for preventing, ameliorating, and / or treating a skin fibrotic disease, comprising formulating the agent according to any one of [1] to [7].

[0009] According to the present invention, a new method for improving the skin fibrosis of skin fibrosis disease is provided.The results of the examples of one aspect of the present invention suggest that the epoxidized unsaturated fatty acid and its derivatives mobilized by PAFAH2, an oxidized phospholipid degrading enzyme expressed in the epidermis, act on fibroblasts present in the dermis, and suppress skin fibrosis.In addition, this may be a new mechanism of skin fibrosis suppression that is applicable not only to systemic sclerosis but also to other skin fibrosis diseases such as keloids and hypertrophic scars.

[0010] As described above, in skin fibrotic diseases, fibrosis itself has a strong irreversible element, and the disease is often resistant or intractable to existing treatments that target the immune system alone. The agent of the present invention targets lipid metabolism in the local skin environment, rather than the conventional treatment strategies that target the immune system, and has a different mechanism of action from existing treatments, so it is expected that it can be used in combination with existing therapeutic agents.

[0011] Omega-3 and omega-6 fatty acids are not artificially synthesized compounds, but are constantly ingested by humans from foods such as fish oil, animal oil, and vegetable oil. Epoxidized omega-3 fatty acids, in particular, are metabolites derived from omega-3 fatty acids, known as health components. Therefore, unlike conventional cytotoxic treatments, treatments that administer these epoxidized unsaturated fatty acids and their derivatives are expected to have fewer systemic side effects, allowing them to be administered from the early stages of disease and to a wide range of patients with various coexisting diseases. Furthermore, the results of examples according to one aspect of the present invention demonstrate the skin fibrosis improvement effect in experimental animals through subcutaneous injection or topical application, rather than systemic administration, and therefore are expected to have fewer systemic side effects when used in clinical applications to human diseases.

[0012] Figure 1 is a schematic diagram showing omega-3 fatty acids, epoxidized omega-3 fatty acids, and the function of PAFAH2. Figure 1(A) shows the structures of omega-3 fatty acids and epoxidized omega-3 fatty acids, and Figure 1(B) shows the function of PAFAH2. Figure 2 shows the results of quantitative PCR and immunohistochemistry for PAFAH2 using healthy skin and systemic sclerosis (SSc) lesional skin samples. Figure 2(A) shows the mRNA expression level of PAFAH2 in SSc patient skin (n = 12 per group). Error bars indicate the mean ± standard error. *P < 0.05, statistics were obtained using the Mann-Whitney U test. Figure 2(B) shows histological images (Bars = 100 μm) of PAFAH2 immunostaining in the skin of healthy individuals and patients (photographs used as drawing substitutes). Figure 3 shows the effect of epoxidized omega-3 fatty acids on the fibrotic response (increased COL1A1 gene expression) in primary cultured human skin fibroblasts. The mRNA expression level of the fibrotic marker gene (COL1A1) was measured when human fibroblasts were treated with TGFβ1 and the epoxidized omega-3 fatty acids 17,18-EpEPE and 19,20-EpDPE. Figure 4 shows the results of quantitative PCR of PAFAH2 in wild-type mice with fibrosis and thickening following subcutaneous administration of the antitumor antibiotic bleomycin (BLM) and in the fibrosis and thickening skin (BLM-induced scleroderma model). Figure 4(A) shows an explanatory diagram of a BLM-induced scleroderma model mouse. Figure 4(B) shows the level of Pafah2 mRNA expression in the skin of wild-type mice in a BLM-induced scleroderma model 3 weeks after administration. n = 8 per group. The solvent is phosphate-buffered saline (PBS), and BLM refers to 200 μg (200 μl) of BLM dissolved in PBS. Error bars indicate the mean ± standard error. * P < 0.05, statistics were obtained using the Mann-Whitney U test. Figure 5 shows the results of a BLM-induced skin sclerosis model experiment using wild-type and Pafah2 knockout (KO) mice. Figure 5(A) shows skin dermal thickness, Figure 5(B) shows skin hydroxyproline content, and Figure 5(C) shows skin Col1a1 gene mRNA expression levels. n = 8 per group. Error bars indicate the mean ± standard error. * P < 0.05, ** P < 0.01, statistics were obtained using the Mann-Whitney U test. Figure 6 shows the results of subcutaneous administration of epoxidized omega-3 fatty acids to a BLM-induced skin sclerosis model using wild-type mice. Figure 6(A) shows the dermal thickness, Figure 6(B) shows the amount of hydroxyproline in the skin, and Figure 6(C) shows the amount of Col1a1 gene mRNA expression in the skin. n = 10 per group. Error bars indicate the mean ± standard error. * P < 0.05, **P < 0.01, statistics were obtained using the Mann-Whitney U test. Figure 7 shows the results of topical application of epoxidized omega-3 fatty acids to a BLM-induced skin sclerosis model using wild-type mice. Figure 7(A) shows skin dermal thickness, Figure 7(B) shows skin hydroxyproline content, and Figure 7(C) shows skin Col1a1 gene mRNA expression levels. n = 10 and 12 for each group. Error bars indicate the mean ± standard error. * P < 0.05, statistics were performed using the Mann-Whitney U test.

[0013] The present invention will be described below. However, the present invention is not limited to the following preferred embodiments, and can be freely modified within the scope of the present invention. In this specification, when a numerical range is expressed as "lower limit to upper limit," the upper limit may be "equal to or less than" or "less than," and the lower limit may be "equal to or greater than" or "more than."

[0014] <Skin fibrosis inhibitor> One aspect of the present invention relates to a skin fibrosis inhibitor (hereinafter sometimes referred to as "skin fibrosis inhibitor of the present invention") comprising one or more selected from epoxidized unsaturated fatty acids and derivatives thereof.

[0015] The skin fibrosis inhibitor of the present invention contains one or more epoxidized unsaturated fatty acids and their derivatives as an active ingredient, which inhibits activated extracellular matrix production by skin fibroblasts, thereby preventing the onset of fibrosis, inhibiting the progression of fibrosis, or improving or treating fibrosis.

[0016] <Epoxidized unsaturated fatty acids and derivatives thereof> The "epoxidized unsaturated fatty acids" in the "epoxidized unsaturated fatty acids and derivatives thereof" that are the active ingredients of the skin fibrosis inhibitor of the present invention are compounds in which at least one C=C double bond in the molecule of an unsaturated fatty acid is epoxidized. The position and number of epoxidation are not particularly limited as long as the effects of the present invention are achieved. In addition, the epoxidized unsaturated fatty acids may be derivatives that achieve the effects of the present invention.

[0017] The unsaturated fatty acid may be either a monounsaturated fatty acid or a polyunsaturated fatty acid, and is not limited thereto, but examples of the monounsaturated fatty acid include omega-9 fatty acids such as oleic acid, and examples of the polyunsaturated fatty acid include omega-6 fatty acids such as linoleic acid and arachidonic acid, and omega-3 fatty acids such as α-linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid. The unsaturated fatty acid in the present invention is preferably omega-3 fatty acids, omega-6 fatty acids, and omega-9 fatty acids, more preferably omega-3 fatty acids and omega-6 fatty acids, and even more preferably omega-3 fatty acids.

[0018] The number of carbon atoms in the unsaturated fatty acid in the present invention is not limited, but may be, for example, 16 to 36, 18 to 22, or 20 to 22, etc.

[0019] The unsaturated fatty acid may be a naturally occurring unsaturated fatty acid that has been modified, for example, so that the number of carbon atoms in the saturated hydrocarbon chain on the carboxy terminal side of the unsaturated fatty acid is 1 to 14, 10 to 14, or 12 to 14, etc.

[0020] Epoxidized unsaturated fatty acids include, but are not limited to, epoxidized omega-3 fatty acids, epoxidized omega-6 fatty acids, and epoxidized omega-9 fatty acids, with epoxidized omega-3 fatty acids and epoxidized omega-6 fatty acids being preferred, and epoxidized omega-3 fatty acids being more preferred. Specific examples of epoxidized unsaturated fatty acids include, but are not limited to, 8,9-epoxyeicosatrienoic acid (8,9-EET), 11,12-EET, 14,15-EET, 17,18-epoxyeicosatetraenoic acid (17,18-EpETE), and 19,20-epoxydocosapentaenoic acid (19,20-EpDPE), with 17,18-EpETE and 19,20-EpDPE being preferred.

[0021] Derivatives of epoxidized unsaturated fatty acids include, but are not limited to, hydroxylated epoxidized unsaturated fatty acids, such as hydroxylated epoxidized omega-3 fatty acids, hydroxylated epoxidized omega-6 fatty acids, and hydroxylated epoxidized omega-9 fatty acids, with hydroxylated epoxidized omega-3 fatty acids being preferred. Specific examples of derivatives of hydroxylated epoxidized unsaturated fatty acids include, but are not limited to, 12-hydroxy-17,18-epoxyeicosatetraenoic acid (12-OH-17,18-EpETE) and 14-hydroxy-19,20-epoxyeicosapentaenoic acid (14-OH-19,20-EpDPE).

[0022] The epoxidized unsaturated fatty acid and its derivatives may be esterified, etherified, or the like, as long as the effects of the present invention are achieved. They may also have a substituent, and the substitution position and number of the substituents are not particularly limited. Examples of the substituent include, but are not limited to, alkyl groups having 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl, isobutyl, n-pentyl, and n-hexyl), alkoxy groups having 1 to 6 carbon atoms (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, s-butoxy, t-butoxy, isobutyloxy, n-pentyloxy, and n-hexyloxy), halogen atoms (e.g., fluorine, chlorine, bromine, and iodine), amino, hydroxy, carboxy, and oxo groups.

[0023] The epoxidized unsaturated fatty acid and its derivatives may be in the form of a salt, and such salts are preferably pharmacologically and physiologically acceptable salts.Specific examples include, but are not limited to, salts of alkali metals (potassium, sodium, etc.), salts of alkaline earth metals (calcium, magnesium, etc.), ammonium salts, and salts of pharmaceutically acceptable organic amines (tetramethylammonium, triethylammonium, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)aminomethane, lysine, arginine, N-methyl-D-glucamine, etc.).

[0024] The epoxidized unsaturated fatty acid and its derivatives can be prepared, for example, by known methods, or commercially available products can also be used.

[0025] In the present invention, the epoxidized unsaturated fatty acids and their derivatives may be used alone or in a mixture of two or more of them. It is also known that unsaturated fatty acids are oxidized to epoxidized unsaturated fatty acids in vivo. Therefore, for example, fish oil, vegetable oil, etc. containing unsaturated fatty acids may be used as the epoxidized unsaturated fatty acids and their derivatives in the present invention.

[0026] As described above, the fibrosis inhibitor of the present invention contains an epoxidized unsaturated fatty acid and its derivative as an active ingredient, but the fibrosis inhibitor of the present invention may consist of only the active ingredient, or may be formulated by containing various additives as sub-ingredients other than the active ingredient in addition to the active ingredient, as long as the effects of the present invention are not impaired. Formulation can be carried out by known methods.

[0027] Skin fibrosis: Tissue fibrosis is the excessive production and accumulation of connective tissues, such as extracellular matrix, primarily collagen, in tissues, resulting in hardening of the tissue and a decline in its function. Fibrosis is observed in various organs, including the liver, pancreas, lungs, kidneys, bone marrow, and heart, and collagen-producing cells, such as fibroblasts, are thought to be involved in the pathology. Such tissue / organ fibrosis is observed at the onset or progression of disease, and preventing it is important for the prevention and treatment of disease. The fibrosis inhibitor of the present invention has been shown to inhibit collagen production in fibroblasts and is thought to have preventive, ameliorative, or therapeutic effects on fibrosis in general, regardless of the type of organ. Here, in the present invention, "prevention of fibrosis" refers to preventing the onset of fibrosis. Furthermore, "prevention of fibrosis" includes preventing or suppressing further deterioration of fibrotic symptoms at various stages, such as the early stages of onset. "Improvement and treatment of fibrosis" refers to improving, alleviating, or preventing or suppressing the worsening of fibrotic symptoms.

[0028] As described above, the fibrosis inhibitor of the present invention is effective in preventing, ameliorating, or treating diseases accompanied by fibrosis. Examples of such diseases include systemic sclerosis, localized scleroderma, keloids, hypertrophic scars, lupus profundus, dermatofibroma, lichen sclerosus et atrophicus, sclerosing panniculitis, nodular fasciitis, neurofibromatosis, nonalcoholic steatohepatitis (NASH) and its precursor, nonalcoholic fatty liver disease (NAFLD), viral hepatitis, alcoholic liver disease, pulmonary fibrosis (interstitial lung disease), renal fibrosis, and complications thereof, with systemic sclerosis, localized scleroderma, keloids, and hypertrophic scars being preferred.

[0029] In particular, it has been shown in the Examples below that the fibrosis inhibitor of the present invention ameliorates fibrosis by suppressing the expression of type I collagen, an extracellular matrix, in skin fibroblast-like cells. Thus, although not limited thereto, the fibrosis inhibitor of the present invention can prevent, ameliorate, or treat fibrosis, particularly by suppressing increased expression of type I collagen, and may be particularly effective in preventing, ameliorating, or treating fibrosis caused by the mechanism of increased type I collagen expression.

[0030] <Composition> Another aspect of the present invention relates to a composition for preventing, ameliorating, and / or treating a skin fibrotic disease, comprising the fibrosis inhibitor of the present invention (hereinafter, may be referred to as the "composition of the present invention"). Note that all of the matters explained in the section <Fibrosis inhibitor> above apply to the explanation in this section.

[0031] The composition of the present invention contains the fibrosis inhibitor of the present invention as an active ingredient, and is effective, for example, in preventing, ameliorating, or treating diseases accompanied by fibrosis described above in the section <Fibrosis inhibitor>.

[0032] The fibrosis inhibitor and composition of the present invention can be used as a reagent, pharmaceutical, quasi-drug, cosmetic, food or drink, etc. for humans or animals, or can be used as a material or preparation to be incorporated into such a reagent, pharmaceutical, quasi-drug, cosmetic, food or drink, etc. Food and drink includes foods, functional foods, foods for specified health uses, foods for patients, and supplements that are based on the concept of inhibiting fibrosis or preventing or improving fibrosis and that are labeled as such as necessary.

[0033] When the fibrosis inhibitor and composition of the present invention are used as reagents, pharmaceuticals, quasi-drugs, cosmetics, etc., the active ingredient can be formulated by appropriately combining it with other pharmaceutically acceptable ingredients (e.g., carriers, excipients, disintegrants, buffers, emulsifiers, suspending agents, soothing agents, stabilizers, preservatives, antiseptics, surfactants, lubricants, diluents, coating agents, sugar coating agents, flavorings, emulsifying / solubilizing / dispersing agents, pH adjusters, isotonic agents, solubilizing agents, fragrances, colorants, solubilizing aids, physiological saline, etc.). The dosage form when formulated is not particularly limited. Examples of dosage forms include tablets, powders, fine granules, granules, capsules, syrups, solutions, suspensions, emulsions, jellies, injections, topical preparations, inhalants, nasal drops, eye drops, and suppositories.

[0034] When the fibrosis inhibitor and composition of the present invention are used as foods and beverages, the forms of the foods and beverages include various food compositions such as breads, cakes, noodles, confectioneries, jellies, frozen foods, ice cream, dairy products, and beverages, as well as forms similar to the above-mentioned formulations suitable for oral administration (tablets, powders, fine granules, granules, capsules, syrups, etc.).Various forms of foods and beverages can be prepared by appropriately combining epoxidized unsaturated fatty acids and derivatives thereof with other food and beverage ingredients, solvents, softeners, oils, emulsifiers, preservatives, flavorings, stabilizers, colorants, antioxidants, moisturizers, thickeners, etc.

[0035] In this specification, "administering a fibrosis inhibitor or composition to an animal" may be synonymous with "inducing an animal to ingest the fibrosis inhibitor or composition." Intake may be voluntary (ad libitum intake) or forced (forced intake).

[0036] The fibrosis inhibitor and composition of the present invention contain an active ingredient in an amount (i.e., an effective amount) necessary to achieve the expected preventive, ameliorative, and therapeutic effects. The amount of epoxidized unsaturated fatty acids and derivatives thereof, which are the active ingredients in the fibrosis inhibitor and composition of the present invention, generally varies depending on the dosage form, but the amount of the active ingredient can be set, for example, within the range of about 0.01 to 99.9% by mass so as to achieve the desired dosage.

[0037] The fibrosis inhibitor and composition of the present invention may be administered to a subject by oral or parenteral administration (subcutaneous, intradermal, intramuscular, intraperitoneal, intravenous, or intra-arterial injection, transdermal, nasal, transmucosal, etc.) depending on the dosage form. These administration routes are not mutually exclusive, and any two or more of them may be used in combination (e.g., transdermal administration may be performed simultaneously with or after a predetermined time has elapsed after subcutaneous injection). Local administration may be used instead of systemic administration. Administration may also be performed using a drug delivery system to deliver the active ingredient specifically to the target tissue.

[0038] The dosage of the fibrosis inhibitor or composition of the present invention generally varies depending on the patient's symptoms, age, sex, and weight, but those skilled in the art can determine an appropriate dosage. For example, oral administration to an adult can involve administering, for example, approximately 0.01 μg to 1000 mg of the active ingredient, epoxidized unsaturated fatty acid and its derivatives, once or in several divided doses per day. Parenteral administration can involve administering, for example, approximately 0.01 μg to 1000 mg per dose via subcutaneous injection, intramuscular injection, intravenous injection, or transdermal injection. Administration schedules can be, for example, once to several times a day, once every two days, or once every three days. When determining the administration schedule, consideration can be given to the patient's symptoms and the duration of effect of the active ingredient.

[0039] The "subject" here is not particularly limited, and includes humans and non-human mammals (including pet animals, livestock, and laboratory animals, such as mice, rats, guinea pigs, hamsters, monkeys, cows, pigs, goats, sheep, dogs, cats, chickens, and quails) in which inhibition of fibrosis or prevention, amelioration, or treatment of fibrosis is desired. In a preferred embodiment, the subject is humans.

[0040] The fibrosis inhibitor and composition of the present invention may be used alone, but can also be used in combination with a known agent for preventing, improving, or treating fibrosis. By using them in combination, it is expected that the preventive, improving, or therapeutic effects will be enhanced. The preventive, improving, or therapeutic agent used in combination may be contained as a component of the fibrosis inhibitor and composition of the present invention, or may be formulated separately from the fibrosis inhibitor and composition of the present invention and used in combination at the time of use, as long as it does not weaken or eliminate the effects of the fibrosis inhibitor and composition of the present invention.

[0041] <Method> A further aspect of the present invention provides a method for inhibiting fibrosis or a method for preventing, ameliorating, or treating fibrosis (hereinafter, sometimes referred to as the "method of the present invention"), comprising administering or ingesting a fibrosis inhibitor or composition of the present invention to a subject in whom inhibition of fibrosis or prevention, amelioration, or treatment of fibrosis is desired. The method of the present invention may be a therapeutic method or a non-therapeutic method. "Non-therapeutic" is a concept that does not include medical procedures, i.e., surgery, treatment, or diagnosis. The route of administration is not particularly limited, and examples include oral, subcutaneous, intradermal, intramuscular, intraperitoneal, intravenous, intra-arterial, transdermal, nasal, and transmucosal routes. These administration routes are not mutually exclusive, and two or more of them can be used in combination. For the dosage and administration schedule, please refer to the description of the fibrosis inhibitor or composition of the present invention above. According to the present invention, fibrosis can be inhibited safely without causing side effects.

[0042] It is also known that in vivo, epoxidized unsaturated fatty acids are present in the cell membranes of mast cells and the like, and PAFAH2 excises and produces epoxidized omega-3 fatty acids and the like from the cell membranes. Therefore, as a further aspect of the present invention, there is provided a method for inhibiting fibrosis or a method for preventing, ameliorating, or treating fibrosis, which comprises enhancing PAFAH2 activity. Enhancement of PAFAH2 activity can be carried out based on known methods.

[0043] The present invention will be specifically described below with reference to examples, but these are merely examples of the present invention and the scope of the present invention is not limited to these examples.

[0044] <Examination of PAFAH2 Expression in the Skin of Systemic Sclerosis Patients> PAFAH2 expression was examined in the skin of systemic sclerosis (SSc) patients and healthy controls. Skin samples were collected from 12 SSc patients and 12 healthy controls. For quantitative PCR, total RNA was extracted from frozen and stored skin tissue using TRIzol (Thermo Fisher Scientific, Carlsbad, CA). cDNA was synthesized using ReverTra Ace qPCR MasterMix (TOYOBO, Osaka, Japan). mRNA expression was measured using an Applied Biosystems real-time PCR machine (Thermo Fisher Scientific). Human GAPDH was used as the reference gene. TaqMan primers (FAM-MGB ligation, Thermo Fisher Scientific) were used, specifically, a probe for human PAFAH2 (cat # Hs00166473_m1). For immunostaining, sections (5 μm thick) were prepared from formaldehyde-fixed, paraffin-embedded samples and stained with anti-mouse PAFAH2 monoclonal IgG antibody TI10 (prepared as described in Kono N, et al. J Biol Chem. 283(3), 1628-1636 (2008)) and ABC stain (Vector Laboratories, Burlingame, CA). Finally, counterstaining was performed with Mayer's hematoxylin. The results were reproducible, and similar trends were observed in staining of six SSc patients and six healthy controls.

[0045] As described above, we first found that PAFAH2 mRNA expression was significantly reduced in the skin lesions of patients with systemic sclerosis, a typical intractable disease presenting with skin sclerosis (Figure 2(A)). PAFAH2 is expressed in cells thought to be blood cells and fibroblasts in the epidermis and dermis of healthy skin, and immunohistochemical staining revealed that its expression was reduced in patients with systemic sclerosis (Figure 2(B)). This suggests that reduced PAFAH2 expression in the skin may be involved in skin fibrosis and systemic sclerosis. We therefore investigated the role of PAFAH2 and its metabolite, epoxidized omega-3 fatty acids, in the pathogenesis of skin fibrosis and systemic sclerosis.

[0046] <Studying the effects of epoxidized omega-3 fatty acids on the fibrotic response> Fibrosis of organs, including skin, is a pathological condition associated with chronic inflammation, in which fibroblasts are stimulated and activated by cytokines such as transforming growth factor β (TGFβ), resulting in increased production and accumulation of extracellular matrix proteins such as type I collagen, leading to stiffening of the skin and organs. It is known that stimulation by TGFβ increases the expression of the COL1A1 (Collagen type I α1 chain) gene, an indicator of tissue fibrosis, in human primary dermal fibroblasts. Therefore, we planned and conducted experiments using human primary dermal fibroblasts.

[0047] Specifically, human normal skin fibroblasts were collected from healthy volunteers. Sample collection was performed with informed consent. Several millimeter-sized pieces of skin tissue were attached to a dish and immersed in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Fibroblast-like cells proliferated from the tissue within a few days. Cells used in the experiments were up to passage 3–5. Epoxidized omega-3 fatty acids, 17,18-EpETE and 19,20-EpDPE, were purchased from Cayman Chemical (MI, USA). 17,18-EpETE and 19,20-EpDPE were dissolved in PBS at 300 nM each, or an equal volume of ethanol, which had been air-dried, and added to human fibroblasts. After 6 hours, 2.5–10 ng / ml TGFβ1 (R&D Systems, MN, USA) was added and stimulated for 0–24 hours. cDNA was synthesized from cells recovered after stimulation using the same method as in the experiment in Figure 2(A), and quantitative PCR was performed. Human GAPDH was used as the reference gene. The primer sequences used were as follows: human GAPDH forward, 5'-cacccactcctccacctttg-3' (SEQ ID NO: 1), reverse, 5'-ctctcttcctcttgtgctcttgct-3' (SEQ ID NO: 2); human COL1A1 forward, 5'-acagcgtggcctacatggac-3' (SEQ ID NO: 3), reverse, 5'-cgggaggtcttggtggtttt-3' (SEQ ID NO: 4).

[0048] The results showed that the addition of epoxidized omega-3 fatty acids, 17,18-EpEPE or 19,20-EpDPE, reduced the TGFβ-dependent increase in COL1A1 expression (Figure 3), demonstrating the anti-fibrotic effects of epoxidized omega-3 fatty acids.

[0049] <Investigating the Relationship between Skin Fibrosis and PAFAH2> A mouse model of skin fibrosis induced by BLM (British LM-induced scleroderma) is available [Yamamoto T, et al. Clin Immunol 102(1), 77-83 (2002)]. Specifically, BLM was dissolved in phosphate-buffered saline (PBS) and 200 μg (200 μl) of the BLM solution was injected into the dorsal skin of wild-type mice once daily for three weeks (Figure 4(A)). The vehicle control group received 200 μl of PBS injection into the dorsal skin. All mice were 8 weeks old at the start of BLM administration. The dorsal skin was collected the day after the final injection and used for analysis. Skin samples were collected from eight mice in the BLM-treated group and eight mice in the PBS-treated group. Twenty-one days after subcutaneous administration of BLM, cDNA was synthesized from fibrotic and thickened skin using the same method as in the experiment in Figure 2(A), and mRNA expression levels were measured using an Applied Biosystems real-time PCR machine. Mouse Gapdh was used as the reference gene. TaqMan primers were used for the primer sequence, specifically, a probe for mouse Pafah2 (cat #Mm00505684_m1).

[0050] As a result, decreased Pafah2 expression was observed, similar to that observed in human systemic sclerosis skin (Figure 4(B)). The results of Figure 2(B) and this Figure 4 indicate that the skin of the BLM-induced scleroderma model mice exhibits decreased PAFAH2 expression, similar to that observed in human systemic sclerosis skin. Based on this, we believe that the BLM-induced scleroderma model mice are useful as an analytical tool for human skin fibrosis.

[0051] <Analysis of the Function of PAFAH2 in Skin Fibrosis> Based on the results shown in Figure 4, we performed a BLM-induced scleroderma model in Pafah2-deficient mice (J Biol Chem. 2008;283(3):1628-1636) and wild-type mice [genetic background: C57BL / 6 NCR mice (Nippon SLC, Hamamatsu, Japan)] to examine the role of PAFAH2 in skin fibrosis. Specifically, as in the experiment shown in Figure 4, 200 μg (200 μl) of BLM solution dissolved in PBS was injected into the skin of Pafah2-deficient mice (n = 8) and wild-type mice (n = 8) once daily for 3 weeks. Mouse skin samples were fixed in 10% formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (HE). Five randomly selected sites per sample were measured for dermal thickness, and the average thickness was calculated for each sample. Skin thickness was defined as the distance from the top of the epidermal granular layer to the boundary between the dermis and subcutaneous panniculus. Hydroxyproline, an amino acid synthesized through post-translational modification of proline by prolyl hydroxylase, is rarely found in proteins other than collagen and is therefore used as a specific marker for quantifying collagen content. Measurements were performed using a Hydroxyproline Colorimetric Assay Kit (BioVision, CA, USA). Specifically, mouse dorsal skin samples were hydrolyzed in 6 N HCl at 95°C for 20 hours. Hydroxyproline in the hydrolyzed samples was reacted with chloramine T to convert it to pyrrole, which was then reacted with dimethylaminobenzaldehyde and detected at 560 nm. The hydroxyproline content of each sample was calculated using a calibration curve. cDNA was prepared from frozen skin samples using the same method as in Figure 2(A), and the expression levels of the Col1a1 gene in the tissues were compared by quantitative PCR.

[0052] As a result, the skin of Pafah2-deficient mice showed thickened dermis, increased hydroxyproline, and increased Col1a1 gene expression by quantitative PCR compared to wild-type mice (Fig. 5 (A), (B), (C)). These findings suggest that the BLM-induced scleroderma model not only closely reflects the phenomena observed in human systemic sclerosis skin, but also that PAFAH2 and the epoxidized omega-3 fatty acids released by this enzyme have an inhibitory effect on skin fibrosis.

[0053] <Effect of Epoxidized Omega-3 Fatty Acids on Skin Fibrosis> Therefore, we next used this mouse model to investigate the clinical applicability of epoxidized omega-3 fatty acids as a novel anti-dermal fibrosis drug. In wild-type mice, we simultaneously subcutaneously injected epoxidized omega-3 fatty acids (a cocktail of 17,18-EpETE and 19,20-EpDPE) into BLM-induced scleroderma-like skin sclerosis. Specifically, 30 ng of each of 17,18-EpETE and 19,20-EpDPE was air-dried and dissolved in 200 μl of PBS. Administration began at the start of the BLM subcutaneous injection. 30 minutes before BLM administration, the drug-treated group (n = 10) received subcutaneous injections of epoxidized omega-3 fatty acids, while the vehicle control group (n = 10) received daily subcutaneous injections of PBS alone. Evaluations were performed using the same methods as in Figure 5, comparing dermal thickness, hydroxyproline content, and Col1a1 gene expression levels.

[0054] As a result, compared to the group administered with the vehicle alone, the group administered with epoxidized omega-3 fatty acids showed a decrease in dermal thickness, a decrease in hydroxyproline content, and even a decrease in Col1a1 gene expression (Figure 6 (A), (B), and (C)).

[0055] Next, to determine whether topical application of epoxidized omega-3 fatty acids could produce similar effects as subcutaneous administration, we evaluated topical application of epoxidized omega-3 fatty acids. Specifically, 17,18-EpETE and 19,20-EpDPE were dissolved in ethanol at 100 ng / ml each, and 10 μl was applied to a 1 cm x 1 cm area on the back of mice. Application began at the start of the subcutaneous BLM injection. 30 minutes before BLM administration, the drug-treated group (n = 12) received topical application of epoxidized omega-3 fatty acids, while the vehicle control group (n = 10) received topical application of ethanol alone. Evaluation was performed using the same method as in Figure 5, comparing dermal thickness, hydroxyproline content, and Col1a1 gene expression levels.

[0056] As a result, similar to the subcutaneous injection, the group receiving topical application of epoxidized omega-3 fatty acids showed a decrease in dermal thickness, a decrease in hydroxyproline content, and a decrease in Col1a1 gene expression compared to the group receiving solvent (Figure 7 (A), (B), and (C)).

[0057] These results suggest that epoxidized omega-3 fatty acids may have clinical application as anti-dermal fibrosis agents.

[0058] As described above, the present invention has revealed that epoxidized unsaturated fatty acids such as epoxidized omega-3 fatty acids and their derivatives suppress the production of extracellular matrix such as type I collagen by skin fibroblasts.

[0059] Furthermore, the present invention suggests that subcutaneous injection and topical application of epoxidized unsaturated fatty acids and their derivatives improves skin fibrosis in mice, and therefore may be a novel treatment for skin fibrosis, including systemic sclerosis, a designated intractable disease, in subjects including humans.

[0060] In addition, the administration method of epoxidized unsaturated fatty acids and their derivatives can be subcutaneous injection or topical application, which is intended to reduce systemic side effects, and the results are expected to be applied to clinical practice. Note that existing treatments mainly involve the systemic administration of steroids or immunosuppressants, which have problems with susceptibility to infection and other systemic side effects, so the local administration of epoxidized unsaturated fatty acids and their derivatives according to the present invention may be presented as a treatment method that is safer than existing treatments.

[0061] This invention is based on the results of studies using human clinical specimens from patients with systemic sclerosis and human cell lines. Furthermore, the BLM-induced mouse model of fibrosing scleroderma used in this study was confirmed to be consistent with the phenomena observed in human clinical specimens. It is believed that the results obtained from mouse experiments are also applicable to human fibrotic lesions.

[0062] For the reasons described above, it is believed that subcutaneous injection or topical application of epoxidized unsaturated fatty acids such as epoxidized omega-3 fatty acids and their derivatives can be clinically applied as a new treatment for fibrotic skin diseases, including systemic sclerosis, which is a designated intractable disease.

Claims

1. A skin fibrosis inhibitor comprising one or more members selected from epoxidized unsaturated fatty acids and their derivatives.

2. The agent according to claim 1, wherein the derivative of an epoxidized unsaturated fatty acid is a hydroxylated epoxidized unsaturated fatty acid.

3. The agent according to claim 1, wherein the epoxidized unsaturated fatty acid is an epoxidized omega-3 fatty acid, an epoxidized omega-6 fatty acid or an epoxidized omega-9 fatty acid.

4. The agent according to claim 1, wherein the epoxidized unsaturated fatty acid has 16 to 36 carbon atoms.

5. The agent according to claim 1, wherein the epoxidized unsaturated fatty acid is an epoxidized omega-3 fatty acid.

6. The agent according to claim 1, wherein the epoxidized unsaturated fatty acid is 17,18-epoxyeicosatetraenoic acid (17,18-EpETE) or 19,20-epoxydocosapentaenoic acid (19,20-EpDPE).

7. The agent described in claim 1, which suppresses the expression of type I collagen.

8. A composition for preventing, improving and / or treating a skin fibrotic disease, comprising the agent according to claim 1.

9. The composition of claim 8, wherein the skin fibrotic disease is selected from systemic sclerosis, localized scleroderma, keloids, hypertrophic scars, lupus profundus, dermatofibroma, lichen sclerosus atrophicus, sclerosing panniculitis, nodular fasciitis, and neurofibromatosis.

Citation Information

Patent Citations

  • CYP450 lipid metabolites that reduce inflammation and angiogenesis

    JP2016505016A

  • Fatty acid derivatives and their uses

    JP2020526505A

  • Novel Anti-inflammatory metabolite derived from omega-3-type fatty acid

    WO2012023254A1

  • Method of treating or limiting development of heart failure with preserved ejection fraction and tissue fibrosis

    WO2013116194A2